Hero

Interview of Filippo Petti, CEO of Celyad before ringing the closing bell at Nasdaq

1

Interview of Filippo Petti, CEO of Celyad before ringing the closing bell at Nasdaq

Celyad Presents Update on Autologous & Allogeneic NKG2D-based CAR-T Therapies in Solid Tumors

2

Celyad Presents Update on Autologous & Allogeneic NKG2D-based CAR-T Therapies in Solid Tumors

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

Latest News

Celyad Presents Update on Autologous & Allogeneic NKG2D-based CAR-T Therapies in Solid Tumors

Celyad Presents Update on Autologous & Allogeneic NKG2D-based CAR-T Therapies in Solid Tumors

Celyad to Host Conference Call to Review Clinical Update from ESMO 21st World GI Congress

Celyad to Host Conference Call to Review Clinical Update from ESMO 21st World GI Congress

Celyad Announces Strategic Updates to the Autologous r/r AML and MDS Program

Celyad Announces Strategic Updates to the Autologous r/r AML and MDS Program

Discover all news

Carousel

Social Feed

Yesterday, @filpetti, @CelyadSA CEO rang the @Nasdaq Closing Bell. $CYAD #CYAD https://t.co/tmRPCQYjKA … https://t.co/ldG5dUjGf3

4 days ago

Yesterday, @filpetti, @CelyadSA CEO rang the @Nasdaq Closing Bell. $CYAD #CYAD https://t.co/tmRPCQYjKA … https://t.co/ldG5dUjGf3

RT @medcitynews: .@CelyadSA presents preliminary allogeneic CAR-T #celltherapy data in colorectal cancer at @myESMO #ESMOgi. Story by @biot…

5 days ago

RT @medcitynews: .@CelyadSA presents preliminary allogeneic CAR-T #celltherapy data in colorectal cancer at @myESMO #ESMOgi. Story by @biot…

Join @CelyadSA conference call today at 2PM CEDT / 8AM EDT $CYAD #CYAD #Immunotherapy https://t.co/Tyy4ZLtDPN https://t.co/0Q4XnzyHrd

1 week ago

Join @CelyadSA conference call today at 2PM CEDT / 8AM EDT $CYAD #CYAD #Immunotherapy https://t.co/Tyy4ZLtDPN https://t.co/0Q4XnzyHrd

Today Professor Dr. Eric Van Cutsem from the UZ Leuven presented preliminary interim data from the ongoing SHRINK a… https://t.co/ZM9ZFBKAs2

1 week ago

Today Professor Dr. Eric Van Cutsem from the UZ Leuven presented preliminary interim data from the ongoing SHRINK a… https://t.co/ZM9ZFBKAs2

Yesterday, @filpetti, @CelyadSA CEO rang the @Nasdaq Closing Bell. $CYAD #CYAD https://t.co/tmRPCQYjKA … https://t.co/ldG5dUjGf3

4 days ago

Yesterday, @filpetti, @CelyadSA CEO rang the @Nasdaq Closing Bell. $CYAD #CYAD https://t.co/tmRPCQYjKA … https://t.co/ldG5dUjGf3

RT @medcitynews: .@CelyadSA presents preliminary allogeneic CAR-T #celltherapy data in colorectal cancer at @myESMO #ESMOgi. Story by @biot…

5 days ago

RT @medcitynews: .@CelyadSA presents preliminary allogeneic CAR-T #celltherapy data in colorectal cancer at @myESMO #ESMOgi. Story by @biot…

Join @CelyadSA conference call today at 2PM CEDT / 8AM EDT $CYAD #CYAD #Immunotherapy https://t.co/Tyy4ZLtDPN https://t.co/0Q4XnzyHrd

1 week ago

Join @CelyadSA conference call today at 2PM CEDT / 8AM EDT $CYAD #CYAD #Immunotherapy https://t.co/Tyy4ZLtDPN https://t.co/0Q4XnzyHrd

Today Professor Dr. Eric Van Cutsem from the UZ Leuven presented preliminary interim data from the ongoing SHRINK a… https://t.co/ZM9ZFBKAs2

1 week ago

Today Professor Dr. Eric Van Cutsem from the UZ Leuven presented preliminary interim data from the ongoing SHRINK a… https://t.co/ZM9ZFBKAs2